Description
A kit of 10 vials of blended CJC-1295 no DAC + Ipamorelin. Each vial contains 5mg of lyophilized CJC-1295 no DAC and 5mg of Ipamorelin.
CJC-1295 without DAC, commonly referred to as Modified GRF(1-29), is a short-acting analogue of growth hormone-releasing hormone (GHRH), while Ipamorelin is a selective growth hormone secretagogue that activates the ghrelin receptor, or GHSR-1a. Both stimulate endogenous growth hormone release, but they act through different receptor systems.
The rationale for combining them is that GHRH-receptor signaling and ghrelin-receptor signaling can interact to produce a greater growth hormone response than either pathway alone. CJC-1295 no DAC provides a relatively short-lived GHRH stimulus, while Ipamorelin independently stimulates GH release through the growth hormone secretagogue receptor. This makes the combination particularly interesting for research into pulsatile GH secretion.
Potential benefits suggested by their combined pharmacology include increased endogenous GH release, higher downstream IGF-1 signaling, improved recovery, changes in body composition, increased fat metabolism, and possible effects on sleep and tissue repair.
One proposed advantage of the short-acting GHRH component is that it produces a transient stimulus rather than continuously elevating GHRH activity. This more closely resembles the body's natural pulsatile pattern of GH secretion. Ipamorelin can amplify the resulting GH pulse while generally producing substantially less ACTH, cortisol, and prolactin stimulation than older growth hormone secretagogues such as GHRP-2 and GHRP-6.





